JENA, Germany, July 31, 2025 — InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company specializing in anti-inflammatory therapeutics by targeting the complement system, announced today that it will report its financial and operating results for the second quarter of 2025 on August 7, 2025, before the market opens. No conference call is scheduled.
About InflaRx
InflaRx (Nasdaq: IFRX) is a biopharmaceutical firm leading the development of anti-inflammatory treatments. The company employs its proprietary anti-C5a and anti-C5a receptor technologies to discover, develop, and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor. C5a is a powerful inflammatory mediator involved in the progression of various inflammatory diseases. InflaRx has developed vilobelimab, a novel, intravenously delivered, first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability across multiple clinical studies. Additionally, InflaRx is developing INF904, an orally administered small molecule inhibitor designed to block C5a-induced signaling via the C5a receptor. InflaRx was founded in 2007, and the group maintains offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For additional information, please visit www.inflarx.de.
InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (collectively referred to as InflaRx).
Contacts:
| InflaRx N.V. | MC Services AG |
| Jan Medina, CFA Vice President, Head of Investor Relations Email: |
Katja Arnold, Laurie Doyle, Dr. Regina Lutz Email: Europe: +49 89-210 2280 U.S.: +1-339-832-0752 |
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All statements herein that are not statements of historical fact are considered forward-looking statements, often identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential,” or “continue,” among others. Forward-looking statements appear in multiple sections of this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations, and the risks, uncertainties, and other factors detailed under the headings “Risk factors” and “Cautionary statement regarding forward looking statements” in our periodic filings with the SEC. These statements are valid only as of the date of this press release and involve known and unknown risks, uncertainties, and other significant factors that could cause our actual results, performance, or achievements to differ materially from any future results, performance, or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties, and other factors, you should not place undue reliance on these forward-looking statements, and we undertake no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.
